𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women

✍ Scribed by Miguel A. Navarro; Ricard Mesía; Orland Díez-Gibert; Antonio Rueda; Belén Ojeda; María C. Alonso

Book ID
110228914
Publisher
Springer US
Year
1997
Tongue
English
Weight
20 KB
Volume
42
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vascular endothelial growth factor and p
Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer
✍ Franca De Paola; Anna Maria Granato; Emanuela Scarpi; Franco Monti; Laura Medri; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 101 KB

## Abstract Vascular endothelial growth factor (VEGF) has emerged as one of the most important angiogenic growth factors from experimental __in vitro__ and __in vivo__ studies. In the present study, we investigated the relationship between VEGF expression and microvessel density (MVD) and defined t

Patients' views of routine hospital foll
Patients' views of routine hospital follow-up: a qualitative study of women with breast cancer in remission
✍ Ruth Adewuyi-Dalton; Sue Ziebland; Eva Grunfeld; Angela Hall 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

Objecti6e: To investigate the experience of specialist hospital follow-up among 109 women with breast cancer in remission. Methods: Qualitative interviews explored views of follow-up at an outpatient clinic. Results: Continuity of care and an unrushed consultation were considered to be both desirabl

Serum epidermal growth factor receptor/H
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer
✍ Christopher Souder; Kim Leitzel; Suhail M. Ali; Laurence Demers; Dean B. Evans; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR, HER‐1, and __erbB__1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. ## METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a